For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Although myeloid neoplasms (MNs) are a known potential adverse effect of chimeric antigen receptor (CAR) T-cell therapy—associated with severe neurotoxicity and survival of less than 1 year1,2—more data are needed on MNs post CAR T to optimize patient counseling, risk stratification, and surveillance among patients with B-cell lymphoproliferative disorders (LPDs) or multiple myeloma (MM), according to a new study.
Blood cancer treatment | Image credit: ployker-stock.adobe.com
Findings from this analysis of incidence rates and factors associated with MNs following CAR T were published online today in JAMA Oncology.3 All patients in this analysis had LPDs or MMs, received CAR T, and were treated for post–CAR T MNs at Mayo Clinic locations in Arizona, Florida, and Minnesota between June 1, 2016, and December 31, 2021. Patients with LPDs or MM (n = 20) were matched 6:1 to patients who also received CAR T but did not develop MNs (the control group; n = 120). Hematologic toxicity was evaluated via CAR-HEMATOTOX score (0-1, low; > 2, high4).
Overall, 20 patients—60% female patients, median (IQR) age, 67 (52-76) years—had developed MNs following CAR T infusion by a median 10 (5018) months. This was seen with a median follow-up of 14 (6-23) months. Measuring incidence rates of post–CAR T MNs at 1, 2, and 3 years after infusion, the investigators saw comparable rates of 4%, 6%, and 9%, respectively, between the patients treated for LPDs or MM.
Clonal hematopoiesis was seen in 64% of the patients who developed MNs, with TP53 and PPM1D being the primary genes involved.
Univariate analysis showed a higher risk of developing MNs if the patient was older, at 65 years or more vs younger than 65 years (HR, 4.99; 95% CI, 1.81-13.76; P = .002); had a low platelet count, at more than 140,000/mcL vs 140,000/mcL or less (HR, 3.69; 95% CI, 1.34-10.18; P = .01); and had a low hemoglobin level, at 9 g/dL or less vs more than 9 g/dL (HR, 2.96; 95% CI, 1.21-7.25; P = .02).
Four additional pairwise multivariate analyses were conducted to evaluate the effects of age 65 and older/hemoglobin level of 9 g/dL or less (Model A), 65 years and older/platelet count of 140,000/mcL or less (Model B), hemoglobin level of 9 g/dL or less/ platelet count of 140,000/mcL or less (Model C), and CAR-HEMATOTOX score of 2 or higher/age 65 and older (Model D).
Only Model B (65 years and older/platelet count of 140,000/mcL or less) was favored by concordance index (0.776), a tool that evaluates prediction model performance. Having 1 factor indicated intermediate risk of developing MNs (4 cases per 100 person-years) and having the 2 factors, high risk (27 cases per 100 person-years); 16% of the patients were considered high risk and 48%, low risk (P < .001). There were more than 80 years of follow-up with this model, and no post–CAR T MNs were seen among the low-risk patients (43%).
Limitations of these findings include that a direct link between CAR T and development of MNs was not possible because the authors noted that every patient had a history of prior cytotoxic therapy, the use of next-generation sequencing prior to CAR T is still considered an investigational method, and there was a lack of independent cohort validation.
“Furthermore, hazard ratios derived from controls reflect an enriched sample and are not generalizable,” they concluded. “Instead, incidence rates calculated from patients receiving commercial CAR T are informative. These observations require confirmation in larger multicenter or registry-based studies.”
References
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More